Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

New Synthetic Cannabinoids May Pose Health Risk

Am J Addictions; ePub 2017 Nov 6; Papadopoulos, et al

Publish date:: November 30, 2017

New synthetic cannabinoid (SC) compounds may pose a different or more severe risk than those previously identified, according to a recent study that assessed SC outbreaks from 2011–2012 and 2015, utilizing The National Poison Data System to collect reports of SC adverse effects in New York State (n= 713). Investigators found:

Cases from 2015 were more likely to be admitted to intensive care units and had different symptoms than those in 2011–2012.
2 new SC structural classes were identified from the 2015 samples.
The 2015 outbreak was associated with more severe SC-related illnesses than in 2011–2012.

Citation:

Papadopoulos EA, Cummings KR, Marraffa JM, Aldous KM, Li L, Ahmad N. Reports of adverse health effects related to synthetic cannabinoid use in New York State. [Published online ahead of print November 6, 2017]. Am J Addictions. doi:10.1111/ajad.12636.

This Week's Must Reads

MDD: Modest improvements in female sexual functioning with adjunctive brexpiprazole,

Transcranial direct current stimulation not clinically relevant in MDD,

Interleukin-1 β and TNF-α hamper antidepressant response in MDD,

Impact of pimavanserin on anxious depression in patients with MDD,

Prior MDD moderates the association between endothelin-1 and post-ACS depressive symptoms,

Must Reads in Addiction Medicine

E-cigarette use tied to increased COPD, asthma risk,

National lung cancer screening guidelines may miss younger African American individuals at high risk,

Alcohol problems linked to legal performance-enhancement products,

Report describes intoxication with new psychoactive substance,

Adolescent alcohol, opioid misuse linked to risky behaviors,